Tocopherol-human serum albumin nanoparticles enhance lapatinib delivery and overcome doxorubicin resistance in breast cancer.
Nanomedicine (Lond)
; 19(16): 1431-1448, 2024 07 02.
Article
em En
| MEDLINE
| ID: mdl-38953854
ABSTRACT
Introduction:
HER2, a tyrosine kinase receptor, is amplified in HER2-positive breast cancer, driving cell signaling and growth.Aim:
This study aimed to combat multidrug resistance in Dox-insensitive breast adenocarcinoma by creating a nanoformulation therapy with a tyrosine kinase inhibitor.Methodology:
Human serum albumin (HSA) was conjugated with α-D-tocopherol succinate to form nanoaggregates loaded with lapatinib (Lapa).Results:
The resulting Lapa@HSA(VE) NPs were 117.2 nm in size and demonstrated IC50 values of 10.25 µg/ml on MCF7 (S) and 8.02 µg/ml on MCF7 (R) cell lines.Conclusion:
Lapa@HSA(VE) NPs showed no hepatotoxicity, unlike free Lapa, as seen in acute toxicity studies in rats.
[Box see text].
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Doxorrubicina
/
Resistencia a Medicamentos Antineoplásicos
/
Nanopartículas
/
Albumina Sérica Humana
/
Lapatinib
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Índia
País de publicação:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM